Edgewise Therapeutics Updates EDG-7500 Phase 2 Trial Progress, Shares Rise 17.96%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Source: Benzinga
- Clinical Trial Progress: Edgewise Therapeutics reported updates from the CIRRUS-HCM Phase 2 trial of EDG-7500, with 43 participants completing dosing across various cohorts, indicating clinical activity in treating hypertrophic cardiomyopathy (HCM) while maintaining a favorable safety profile.
- Safety Analysis: Among the 20 participants who completed 12 weeks of dosing, EDG-7500 demonstrated good tolerability with no significant changes in left ventricular ejection fraction (LVEF), supporting its potential use across diverse HCM patient populations.
- Future Plans: The company is on track to deliver comprehensive efficacy and safety data from Part D of the CIRRUS-HCM trial in Q2 2026 and plans to initiate Phase 3 trials by the end of 2026, further advancing product development.
- Market Reaction: Following the trial updates, Edgewise Therapeutics shares rose 17.96% to $25.65, reflecting positive market sentiment regarding its clinical progress.
Analyst Views on EWTX
Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 38.14 USD with a low forecast of 16.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 29.360
Low
16.00
Averages
38.14
High
51.00
Current: 29.360
Low
16.00
Averages
38.14
High
51.00
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
